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Cysteine protease inhibitors kill malaria parasites and are being pursued for development as antimalarial
agents. Because they have multiple targets within bloodstream-stage parasites, workers have assumed that
resistance to these inhibitors would not be acquired easily. In the present study, we used in vitro selection to
generate a parasite resistant to growth inhibition by leupeptin, a broad-profile cysteine and serine protease
inhibitor. Resistance was not associated with upregulation of cysteine protease activity, reduced leupeptin
sensitivity of this activity, or expression level changes for putative cysteine or serine proteases in the parasite
genome. Instead, it was associated with marked changes in the plasmodial surface anion channel (PSAC), an
ion channel on infected erythrocytes that functions in nutrient and bulky organic solute uptake. Osmotic
fragility measurements, electrophysiological recordings, and leupeptin uptake studies revealed selective re-
ductions in organic solute permeability via PSAC, altered single-channel gating, and reduced inhibitor affinity.
These changes yielded significantly reduced leupeptin uptake and could fully account for the acquired resis-
tance. PSAC represents a novel route for the uptake of bulky hydrophilic compounds acting against intraeryth-
rocytic parasite targets. Drug development based on such compounds should proceed cautiously in light of
possible resistance development though the selection of PSAC mutants.
Malaria is a leading cause of morbidity and mortality world-
wide. Each year, up to 500 million humans are infected and 1
million to 2 million die as a result of infection with Plasmodium
falciparum, the most virulent human parasite. Acquired para-
site resistance to all available antimalarial drugs, combined
with the absence of an approved vaccine, has created a des-
perate need to identify new parasite targets for drug develop-
ment.
One group of parasite targets that has recently received
much attention is the cysteine proteases. Several factors have
contributed to this growing interest. A large number of puta-
tive cysteine proteases have been identified in the completed
parasite genome sequence (22). A drug that inhibits several of
these enzymes may be less susceptible to resistance because of
its multiple sites of action. Moreover, cell biological studies
have identified a divergent collection of essential activities
mediated by these cysteine proteases. These include digestion
of hemoglobin by intraerythrocytic parasites (24), timed eryth-
rocyte rupture and release of invasive merozoites (7, 28, 38),
host cell invasion (6), and processing of various preproteins.
Finally, functional screens have identified a number of cysteine
protease inhibitors with established in vitro and in vivo activ-
ities against malaria parasites (23, 26).
Important hurdles in translating these advances into a clin-
ically useful antimalarial drug include toxicity due to inhibition
of human proteases, the generally short half-lives of peptido-
mimetic agents in vivo, and unforeseen resistance mechanisms.
The availability of protease enzymatic assays, libraries of
known small-molecule protease inhibitors, and crystal struc-
tures of some parasite proteases have helped identify inhibitors
with improved specificity and stability. Resistance mechanisms
for cysteine protease inhibitors appear to be more complex and
have not been as extensively studied. One study used in vitro
selection with gradually escalating concentrations of a vinyl
sulfone protease inhibitor to generate a highly resistant para-
site isolate (31). Functional and genetic analyses of the se-
lected mutant suggested that both upregulated expression of
two falcipain cysteine proteases and reduced access to its tar-
gets in infected cells may contribute to resistance.
We now report the in vitro selection and characterization of
a parasite resistant to leupeptin, a more readily available cys-
teine protease inhibitor. In vitro resistance was stable for many
generations after removal of leupeptin pressure, suggesting
changes at the level of the parasite genome. Surprisingly, our
functional studies with this mutant revealed that basal cysteine
protease activity was not upregulated and that its leupeptin
sensitivity was unchanged. Instead, resistance was linked to
marked changes in the plasmodial surface anion channel
(PSAC), a parasite-induced ion channel on the host erythro-
cyte membrane that mediates the uptake of nutrients and var-
ious bulky organic solutes. These changes were associated with
reduced leupeptin entry into infected erythrocytes, which ap-
pears to be the primary resistance mechanism. Our findings
implicate an important role for PSAC in the uptake of water-
* Corresponding author. Mailing address: Laboratory of Malaria
and Vector Research, NIAID, NIH, Room 3W-01, 12735 Twinbrook
Parkway, Rockville, MD 20852-8132. Phone: (301) 435-7552. Fax:
(301) 402-2207. E-mail: sdesai@niaid.nih.gov.
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soluble antimalarial drugs with low intrinsic membrane perme-
ability. In addition, selection of PSAC mutants conferring re-
duced uptake represents a novel resistance mechanism that
should be considered by antimalarial drug development pro-
grams. We present a straightforward test that can be used with
any drug candidate to determine whether this type of resis-
tance may arise.
MATERIALS AND METHODS
Reagents. Leupeptin hemisulfate and SYBR green I were obtained from
Invitrogen (Carlsbad, CA); 2-butyl-5-imino-6-{[5-(4-nitrophenyl)-2-furyl]methyl-
ene}-5,6-dihydro-7H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-one (NPF-1) was ob-
tained from Chembridge Corp. (San Diego, CA); and N--benzyloxycarbonyl-L-
phenylalanyl-L-arginine-(7-amino-4-methylcoumarin) (Z-Phe-Arg-AMC) was
obtained from AnaSpec (San Jose, CA). Unless otherwise specified, all other
reagents were obtained from Sigma-Aldrich (St. Louis, MO).
Growth inhibition assays. Leupeptin growth inhibition dose-responses were
determined using a SYBR green I-based fluorescence assay for parasite nucleic
acid in 96-well format. Parasite cultures were synchronized in 5% D-sorbitol
before seeding at 0.2 to 0.5% parasitemia and 5% hematocrit in RPMI 1640
supplemented with 25 mM HEPES, 2% serum, 50 mg/liter hypoxanthine, and
leupeptin at indicated concentrations. Cultures were maintained for 5 days at
37°C in 5% O2–5% CO2, with a medium change on day 3. The plates were then
subjected to freezing-thawing before addition of SYBR green I at twice the
manufacturer’s recommended final concentration, incubation in the dark for 30
min, and measurement of fluorescence (excitation and emission at 485 and 528
nm, respectively). Growth inhibition studies with known antimalarials and other
protease inhibitors were similarly performed, except that shorter incubation
times (72 h) were used for blasticidin S, chloroquine, artemisinin, and quinine.
For each inhibitor concentration, the mean of triplicate measurements was
calculated after subtraction of background fluorescence from cultures killed by
20 M chloroquine.
Incubations for 72 h were also used for growth inhibition studies that examined
the effect of NPF-1, a specific PSAC antagonist (15), on leupeptin’s toxic effect.
These experiments used serial dilutions of various molar ratios of leupeptin and
NPF-1. For each ratio, the concentrations required to produce 50% parasite
killing (IC50s) were determined by interpolation and are presented in a standard
isobologram plot (18).
Transmission electron microscopy. Specimens were fixed overnight at 4°C
with 2.5% glutaraldehyde–4% paraformaldehyde in 0.1 M sodium cacodylate
buffer, pH 7.4. They were then postfixed for 1 h with 0.5% osmium tetroxide–
0.8% potassium ferricyanide, stained overnight with 1% uranyl acetate at 4°C,
dehydrated with a graded ethanol series, and embedded in Spurr’s resin. Thin
sections were cut with an RMC MT-7000 ultramicrotome (Ventana, Tucson,
AZ), stained with 1% uranyl acetate and Reynold’s lead citrate, and visualized at
80 kV on a Philips CM-10 transmission electron microscope (FEI Company,
Hillsboro, OR). Digital images were acquired with a digital camera system
(Advanced Microscopy Techniques, Danvers, MA).
Measurement of hemozoin production. Beta-hematin, the principal pigment in
parasite hemozoin, was measured as described previously (20). Briefly, parasites
were synchronized, adjusted to 10% parasitemia, and cultured with 50 M
leupeptin for 18 h to allow maturation to the trophozoite stage and minimize the
effects of leupeptin on later stages. Packed cells were harvested from leupeptin-
treated parasites and untreated controls, lysed in 10 ml of ice-cold 5 mM
Na2HPO4 (pH 7.6), and centrifuged (27,000 g, 30 min). The pellet was washed
and digested overnight at room temperature in 2 ml of 2.5% sodium dodecyl
sulfate–25 mM Tris, pH 7.8. After centrifugation to remove soluble material, the
remaining pellet was incubated in the same solution supplemented with 0.1 N
NaOH to release the ferriprotoporphyrin IX incorporated in beta-hematin. The
pigment released was detected with absorbance wavelength scans and was quan-
tified at 400 nm.
Quantitative reverse transcription-PCR (RT-PCR). Total RNA was harvested
from tightly synchronized mid-trophozoite-stage parasites for cDNA synthesis by
using oligo(dT) and random hexamer primers with Superscript II reverse trans-
criptase (Invitrogen). Matched cDNA from wild-type and HB3-leuR1 parasites
was used as the template in PCR of small amplicons (100 to 150 bp) with specific
primers for genes encoding cysteine, serine, and aspartyl proteases and the
Quantitect SYBR green PCR kit (Qiagen, Valencia, CA). The reaction condi-
tions were those recommended by the manufacturer. Amplification kinetics were
followed in real time (iCycler iQ multicolor real-time PCR system; Bio-Rad,
Hercules, CA). Transcript abundance for each gene was determined relative to
that of 60S ribosomal subunit protein L18 (PlasmoDB accession number
MAL13P1.209), an internal control used in each experiment.
Parasite protease activity and leupeptin sensitivity. Z-Phe-Arg-AMC is a
peptidomimetic substrate for many cysteine and serine proteases. Protease-
mediated hydrolysis yields increased fluorescence through liberation of the AMC
group. We quantified parasite protease activity with this reagent using soluble
parasite extracts prepared as described previously (25), except that trophozoite-
infected erythrocytes were enriched to 95 to 99% parasitemia by Percoll-sorbitol
separation (1). Extracts from HB3 and HB3 leuR1 parasites were adjusted to 40
g/ml (RC DC protein assay; Bio-Rad) in 0.1 M sodium acetate, pH 5.5, with 10
mM dithiothreitol and leupeptin, where indicated, and prewarmed to 37°C in a
96-well plate before addition of 50 M Z-Phe-Arg-AMC. The fluorescence
output was measured at 2-min intervals to estimate the rate of hydrolysis (exci-
tation and emission wavelengths, 353 and 442 nm, respectively).
Erythrocyte leupeptin permeability assays. The Z-Phe-Arg-AMC protease
assay was modified to detect and quantify leupeptin accumulation in erythrocyte
cytosol. For this assay, uninfected or enriched infected erythrocytes were washed,
incubated in phosphate-buffered saline (PBS) with leupeptin for indicated du-
rations at room temperature, and washed four or five times in ice-cold PBS with
5% serum and 500 M furosemide. Control experiments confirmed that these
wash conditions remove all extracellular leupeptin with negligible loss of intra-
cellular leupeptin. Cell number was then determined with a hemocytometer to
standardize measurements between isolates. The erythrocytes were then sus-
pended at 20% hematocrit in PBS with 0.05% saponin for 10 min before cen-
trifugation (4,000  g, 10 min, 4°C). This saponin treatment releases solutes in
the erythrocyte compartment, but not those in the parasite compartment. Su-
pernatant corresponding to the erythrocyte cytosol released from 108 cells was
then resuspended to 1 ml in 0.1 M sodium acetate, pH 5.5, with 10 mM dithio-
threitol–150 ng/ml papain (2.4  105 activity units/ml), incubated for 10 min,
and mixed with 50 M Z-Phe-Arg-AMC in 96-well plates before fluorescence
measurements were obtained as described above.
While these fluorescence measurements resemble those described in the pre-
ceding section, they differ in that only the erythrocyte cytosolic compartment is
used to evaluate and quantify leupeptin transport through channels on the
erythrocyte membrane. Because this compartment has negligible protease activ-
ity, we added papain to catalyze Z-Phe-Arg-AMC hydrolysis. Control experi-
ments revealed that leupeptin has a high affinity for inhibition of papain activity
(IC50, 5 nM), permitting high sensitivity in these measurements.
Osmotic lysis kinetics. Osmotic lysis experiments were performed as described
previously (36). Trophozoite-infected erythrocytes were enriched by Percoll-
sorbitol separation, washed in PBS (150 mM NaCl, 20 mM Na2HPO4, pH 7.5),
and resuspended at 0.5% hematocrit in 280 mM sorbitol, 20 mM sodium
HEPES, 0.1 mg/ml bovine serum albumin, pH 7.4, supplemented with PSAC
antagonists as indicated. Osmotic swelling and lysis were then continuously
monitored by recording transmittance of 700 nm light through the cell suspen-
sion (DU640 spectrophotometer with Peltier temperature control; Beckman
Coulter, Fullerton, CA). This method yields permeability estimates that match
those from radioisotope flux and patch-clamp recordings (36).
Electrophysiology. Cell-attached patch-clamp recordings of trophozoite-stage
infected erythrocytes were obtained as described previously (2) in symmetric
bath and pipette solutions of 1,000 mM choline chloride, 115 mM NaCl, 10 mM
MgCl2, 5 mM CaCl2, 20 mM sodium HEPES, pH 7.4. This hypertonic solution
increases the signal-to-noise ratio for single PSAC detection by permitting higher
rates of Cl flux through open channels and by reducing electrical noise con-
tributed by the pipette. When phloridzin was used in single-channel recordings,
it was present at identical concentrations in both pipette and bath compartments.
Pipettes were fabricated from quartz capillaries by pulling to tip diameters of
0.5 m and resistances of 1 to 3 M in the recording solution. Seal resistances
were100 G. Voltage clamp recordings were obtained with an Axopatch 200B
amplifier (Molecular Devices, Sunnyvale, CA), filtered at 5 kHz with an eight-
pole Bessel filter, digitized at 100 kHz, and recorded with Clampex 9.0 software
(Molecular Devices). All single-channel analyses were carried out with locally
developed code.
Statistical methods. Two-group comparisons used Student’s t test except for
those examining Z-Phe-Arg-AMC hydrolysis rates. For those hydrolysis rates,
paired t test comparisons were used because we noticed day-to-day variations in
the fluorescence signal for this reagent. Confidence intervals on the ratios used
log transformations and t distributions with Student’s degrees of freedom. In
dose-response studies, concentrations producing 50% inhibition (K0.5) were es-
timated by nonlinear least squares fitting to the equation y 	 a/[1  (x/K0.5)b],
where a and b are constants and x and y are the independent and dependent
variables, respectively. b was set equal to 1 except in fits of phloridzin dose-
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responses because this antagonist is known to have a complex stoichiometry of
interaction with PSAC (9). The confidence interval and P value for the ratio of
K0.5 values in Fig. 2 were calculated by weighted least squares fitting of ratios and
variances from individual experiments. These ratios and variances were calcu-
lated by a separate nonlinear least-squares fit for each experiment. Simulations
show that this gives better coverage than combining the results of all experiments
into one mixed-effects nonlinear model. All P values are two sided.
RESULTS
Selection of a leupeptin-resistant P. falciparum clone. Leu-
peptin (acetyl-leucyl-leucyl-arginal; molecular weight, 426.6) is
a competitive, reversible inhibitor of serine and cysteine pro-
teases. As reported previously (24), we found that 50 M
leupeptin sterilizes asexual-stage P. falciparum cultures, with
no viable parasites detected by microscopic examination after
3 days. Upon continued culturing with leupeptin, however,
resistant parasites were recovered within 8 weeks on five sep-
arate attempts. In these studies, several different laboratory
isolates (3D7, HB3, FCB, Indo 1, and 7G8) were challenged
with leupeptin; interestingly, leupeptin-resistant parasites were
recovered only from the HB3 isolate, suggesting an effect of
genetic differences between this and other laboratory isolates.
A clonal population of leupeptin-resistant parasites, referred
to here as HB3-leuR1, was obtained by limiting dilution cul-
tures. Growth inhibition studies with this mutant revealed a
fourfold increase in the leupeptin IC50 (74 
 4 M versus 18 

2 M for the parental HB3 isolate; n	 4 trials each; P 104)
(Fig. 1A). This relatively modest change in IC50 is sufficient to
permit the continuous culture of HB3-leuR1 in the presence of
50 M leupeptin, a concentration that sterilizes cultures of
wild-type isolates.
Leupeptin’s toxic effects may be due to inhibition of pro-
teases expressed at various parasite stages and intracellular
sites; there are nearly 50 predicted cysteine or serine proteases
in the parasite genome that may be targeted (39). To explore
possible resistance mechanisms, we compared the microscopic
effects of leupeptin on HB3 and HB3-leuR1 parasites. As seen
with other parasite isolates (11, 24), intraerythrocytic HB3
parasites exhibited enlarged digestive vacuoles after exposure
to leupeptin; in contrast, HB3-leuR1 parasites had a vacuole
morphology indistinguishable from that of cells not exposed to
leupeptin (data not shown). Transmission electron micro-
graphs confirmed these observations and revealed reduced for-
mation of hemozoin crystals in leupeptin-treated HB3 para-
sites, but crystals of normal size and number in HB3-leuR1
parasites (Fig. 1B). These crystals are formed from the ferri-
protoporphyrin IX released by protease-mediated hemoglobin
digestion. We quantified this difference by measuring the
production of sodium dodecyl sulfate-resistant hemozoin.
When compared to matched controls (HB3 parasites without
leupeptin treatment), leupeptin exposure significantly reduced
production of hemozoin in HB3 parasites, but not in HB3-
leuR1 parasites (Fig. 1C and D). Because the selection of
HB3-leuR1 is associated with restoration of normal vacuole
morphology and hemozoin formation, our studies support the
prevailing view that inhibition of hemoglobin degradation con-
tributes to leupeptin’s toxic effect on wild-type parasites. HB3-
leuR1 may then have acquired resistance by upregulating vac-
uolar proteases, by altering their sensitivity to leupeptin,
through the conversion of leupeptin into inactive metabolites
(4), or by decreasing leupeptin access to these intraerythrocytic
targets.
Leupeptin resistance is not associated with changes in pro-
tease expression or inhibitor sensitivity. Although there are
numerous proteases in the parasite digestive vacuole, two pa-
pain-family (clan CA) cysteine proteases, falcipain-2 and fal-
cipain-3, are critical in hemoglobin digestion (29, 30). We used
hydrolysis of the fluorogenic peptide substrate Z-Phe-Arg-
AMC under buffered conditions that simulate the vacuolar
milieu (25) and found essentially identical cysteine protease
activities in HB3 and HB3-leuR1 parasites (Fig. 2A) (95%
confidence interval for the ratio of HB3-leuR1 hydrolysis rate/
HB3 hydrolysis rate, 0.89 to 1.10). Consistent with the known
pharmacology of these proteases, addition of leupeptin slowed
substrate hydrolysis by extracts from both isolates (Fig. 2B and
FIG. 1. Leupeptin sensitivity and parasite ultrastructure. (A) Leu-
peptin dose-response for in vitro growth inhibition of HB3 and HB3-
leuR1 parasites (filled and open circles, respectively). (B) Transmission
electron micrographs of HB3- and HB3-leuR1-infected erythrocytes
(upper and lower panels, respectively) after culturing with 100 M
leupeptin for 6 h. Parasite digestive vacuoles are demarcated with
white arrows in both panels. While HB3 parasites exhibit swollen
digestive vacuoles with a reduction in hemozoin crystals, HB3-leuR1
parasites exhibit normal vacuolar morphology despite leupeptin expo-
sure. The white scale bar in the lower panel represents 500 nm for both
panels. (C) Absorbance (Abs) scan of solubilized hemozoin produced
during an 18-h incubation with 50 M leupeptin by HB3-leuR1 and
HB3 parasites (upper and lower traces, respectively). AU, arbitrary
units. (D) Mean
 SEM absorbance at 400 nm from the scans in panel
C normalized to 100% for HB3 parasites not exposed to leupeptin.
Hemozoin production in the presence of leupeptin is significantly
greater in HB3-leuR1 (P 	 0.03; n 	 4 trials each).
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C). Leupeptin dose-responses, determined to evaluate possible
changes in inhibitor affinity, were adequately fitted by an equa-
tion based on reversible inhibition in a 1:1 stoichiometry (see
the legend to Fig. 2). The K0.5 values for leupeptin inhibition
were 87 
 3.8 nM and 98 
 6.5 nM for HB3 and HB3 leuR1,
respectively (n 	 4 dose-response experiments each). These
values were not significantly different (P 	 0.433; 95% confi-
dence interval for the HB3-leuR1 K0.5 to HB3 K0.5 ratio, 0.76
to 1.4).
Because functional assays may not detect changes in expres-
sion of some parasite proteases, we evaluated possible upregu-
lation in the mutant by performing real-time two-step RT-PCR
to quantify transcription of a large collection of cysteine,
serine, and aspartyl proteases expressed during intraerythro-
cytic parasite stages (39). In contrast to the acquired resistance
to another protease inhibitor (31), these experiments did not
identify global upregulation of protease genes (Table 1). Some
of these genes may have modest up- or downregulation that
contributes to leupeptin resistance. More extensive studies will
be necessary to determine reproducibility and possible biolog-
ical significance of such changes. We also sequenced the falci-
pain-2 and falcipain-3 genes from both the HB3 and the HB3-
leuR1 parasites and found no mutations between these isolates
(data not shown); there were also no polymorphisms relative to
their sequences in the 3D7 isolate (PF11_0165 and PF11_0162,
respectively). Thus, functional studies, expression profiles, and
DNA sequencing do not implicate changes in parasite pro-
teases as the primary basis of the selected leupeptin resistance.
Altered PSAC activity in HB3-leuR1. We next explored
whether resistance is due to reduced leupeptin uptake by in-
fected erythrocytes. The host erythrocyte membrane repre-
sents a major barrier for the uptake of serum solutes. Bulky
organic solutes enter infected erythrocytes primarily via PSAC,
FIG. 2. Resistance is not associated with changes in protease activity or sensitivity to leupeptin. (A) Mean Z-Phe-Arg-AMC hydrolysis rates 

SEM as a measure of digestive vacuolar protease activity (n 	 5 for each parasite analyzed as matched pairs; P  0.9). (B and C) Leupeptin
dose-responses for vacuolar proteases from wild-type and resistant parasites, respectively. Each symbol represents the mean of three rates
determined by linear regression of fluorescence measurements between 10 and 90 min after addition of extract. The solid curve represents the best
fit of the data to y 	 a/[1  (x/K0.5)]. The insets in each panel show the primary fluorescence data for 0, 100, and 500 nM leupeptin (top to bottom,
respectively) and demonstrate that the hydrolysis of Z-Phe-Arg-AMC proceeds with linear kinetics. AU, arbitrary units.































































a Genes encoding putative proteases were selected on the basis of expres-
sion during erythrocytic stages in a previous study (39). Values represent the
means 
 SEMs of the transcript abundance in HB3-leuR1 relative to that in
HB3, as determined by quantitative RT-PCR (n 	 3 separate RNA harvests
each).
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an unusual broad-specificity ion channel on the host mem-
brane (10). Important examples of these solutes include N-
hydroxysulfosuccinimide esters (5) and pepstatin A (27), an-
other peptidomimetic protease inhibitor. Because leupeptin
may also enter infected erythrocytes via this channel, we eval-
uated PSAC activity on erythrocytes infected with HB3-leuR1.
Organic solute uptake via PSAC can be quantified with a
transmittance-based light scattering assay (36). This assay has
been used to estimate the absolute permeability coefficient for
sorbitol and to determine the affinities of various PSAC antag-
onists (2, 9, 17, 36). Our survey of the functional properties of
PSAC revealed significantly decreased sorbitol permeability in
HB3-leuR1-infected erythrocytes (Fig. 3). We quantified this
decrease with osmotic lysis half-time values of 7.5 
 1.1 and
18.5 
 1.8 min for HB3 and HB3-leuR1, respectively (mean 

standard error of the mean [SEM] for n 	 16 determinations
for each isolate). Because there is a reciprocal relationship
between the lysis half-time and permeability, these values re-
flect a statistically significant decrease in sorbitol permeability
in the HB3-leuR1 parasite (P  105). At 50 M, leupeptin
had no measurable effect on sorbitol uptake with either para-
site, excluding a direct effect of leupeptin on PSAC activity
(data not shown).
We searched for other changes and identified altered affin-
ities for two well-characterized PSAC antagonists. Channels on
cells infected with HB3-leuR1 exhibited a markedly reduced
affinity for inhibition by phloridzin (Fig. 4A and B). Because
phloridzin is not specific (9) and because other channels might
also contribute to organic solute uptake (32), we obtained
cell-attached patch-clamp recordings with and without phlo-
ridzin. Single PSAC recordings from HB3-leuR1-infected
erythrocytes revealed markedly less effective inhibition by 100
M phloridzin than those from HB3-infected erythrocytes
(Fig. 4C). Concordant changes in the osmotic lysis assay and in
single channel recordings are consistent with a primary role for
PSAC in the uptake of diverse organic solutes, as suggested in
various other studies (2, 5, 9, 10, 14, 15, 17).
We also identified a significant reduction in affinity for
furosemide (Fig. 4E), a well-studied and somewhat more spe-
cific PSAC antagonist (2, 8). Because furosemide and phlorid-
zin inhibit PSAC through binding sites on opposite membrane
faces (9), this observation suggests global structural changes in
PSAC on this mutant. The association between the selection of
a mutant parasite and changes in PSAC is also consistent with
the findings of previous studies that suggest that it is parasite
encoded (2, 14).
Changes in PSAC confer drug resistance by reducing leu-
peptin uptake. The altered PSAC behavior of HB3-leuR1 may
contribute to resistance by reducing leupeptin uptake at the
erythrocyte membrane. To test this hypothesis, we modified
the Z-Phe-Arg-AMC hydrolysis protease assay to detect leu-
peptin accumulation in the erythrocyte cytosol. Infected eryth-
rocytes were preincubated with leupeptin, washed to remove
the extracellular protease inhibitor, and then treated with sa-
ponin to permeabilize the erythrocyte membrane without re-
leasing parasite cytosolic components. Erythrocyte cytosol
fractions prepared from infected cells significantly inhibited
Z-Phe-Arg-AMC hydrolysis by papain, while those prepared
from uninfected cells did not (Fig. 5A). Control experiments
using preincubations without leupeptin did not show this dif-
ference (data not shown). Thus, trophozoite-infected erythro-
cytes have a measurably higher leupeptin permeability than
uninfected erythrocytes. This parasite-induced permeability is
mediated by PSAC because it was largely abolished by 50 M
NPF-1 (Fig. 5A), a specific PSAC antagonist (15).
Similar experiments with HB3-leuR1-infected erythrocytes
indicated that they have a significantly lower leupeptin perme-
ability than cells infected with HB3 (Fig. 5B and C; n 	 5 for
each parasite; P 	 2  105). Thus, the altered PSAC con-
tributes to resistance by selectively reducing passive leupeptin
uptake across the erythrocyte membrane.
Various other parasite-induced ion channels on the eryth-
rocyte surface have been reported by other workers (32).
While it remains formally possible that changes in these chan-
nels may also contribute to reduced leupeptin uptake in HB3
leuR1, this is unlikely for several reasons. First, each of these
other proposed channels is thought to represent a human ion
channel activated by the parasite. In vitro selection of specifi-
cally engineered changes in human ion channels permitting
reduced leupeptin entry but the sustained uptake of nutrients
is difficult to envision, especially because erythrocytes lack her-
itable genetic material. Second, NPF-1 has no measurable ac-
FIG. 3. Reduced organic solute permeability of HB3-leuR1-infected erythrocytes. (A) Osmotic lysis kinetics in isotonic sorbitol, determined by
continuous monitoring of 700-nm light transmittance through suspensions of infected erythrocytes. Superimposed dotted lines are used to
determine the time to 50% hemolysis and reveal the slower kinetics of sorbitol uptake by HB3-leuR1-infected erythrocytes. (B) Mean hemolysis
half-times (t1/2) 
 SEM for each parasite.
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tivity against a battery of other ion channels in other systems
(15, 17). To account for the reduced leupeptin uptake in HB3-
leuR1, a channel unrelated to PSAC would need to be present
on the erythrocyte membrane and also be sensitive to NPF-1,
an unlikely coincidence. Third, it is difficult to account for the
changes observed in single PSAC recordings (Fig. 4C) upon in
vitro selection with leupeptin in scenarios in which PSAC is not
involved in organic solute uptake.
FIG. 4. Altered pharmacology links changes to PSAC. (A and B) Osmotic lysis kinetics in sorbitol for the indicated parasites with 0, 100, 500,
1,000, and 5,000 M phloridzin (traces from top to bottom, respectively, in each panel). HB3-leuR1 channels have reduced phloridzin affinity.
(C) Phloridzin dose-responses for HB3 and HB3-leuR1 (open and filled circles, respectively). Each symbol represents the mean 
 SEM from up
to seven osmotic lysis half-times after normalization to 1.0 without phloridzin. Solid lines represent best fits to y 	 a/[1  (x/K0.5)
b], with estimated
K0.5 values of 17 
 0.9 and 340 
 49 M for HB3 and HB3-leuR1, respectively. (D) Single PSAC recordings without (top trace) or with (lower
four traces) 100 M phloridzin added to both the bath and the pipette. The left and right columns reflect recordings from erythrocytes infected
with HB3 and HB3-leuR1, respectively; each column shows traces acquired from three separate patches. For all traces, the membrane potential
was clamped at 100 mV. The dash to the left of each trace represents the closed channel level. Data are typical of five single channel patches
recorded from each isolate. The inhibitor-free channel gating is also visibly altered in comparisons of the two top traces. This altered gating was
seen in other patches and may reflect an additional change in the mutant PSAC. (E) Difference in K0.5 values for inhibition of sorbitol-induced
osmotic lysis by furosemide, estimated as described previously (36). P 	 2.4  105 (Student’s t test) determined from n 	 6 trials each.
FIG. 5. Leupeptin uptake is mediated by PSAC and is decreased in the mutant. (A) Percent inhibition of papain-mediated Z-Phe-Arg-AMC
hydrolysis by erythrocyte cytosol harvested from cells incubated with 40 M leupeptin for 15 min at room temperature. Initial hydrolysis rates were
determined by linear regression of measurements every 2 min for the first 10 min. Bars represent the means 
 SEMs of four independent experiments
with cytosolic fractions from uninfected cells, HB3-infected cells, or HB3-infected cells exposed to 50 M NPF-1 during leupeptin loading (Uninf, Inf,
and Inf  NPF-1, respectively). (B) Kinetics of papain-mediated Z-Phe-Arg-AMC hydrolysis in the presence of infected erythrocyte cytosolic fractions
prepared before or after a 60-min incubation with 40 M leupeptin at 37°C (circles and triangles, respectively). Symbols represent means 
 SEMs of
triplicate readings with erythrocyte cytosol from HB3- and HB3-leuR1-infected cells (black and white symbols, respectively). Sustained Z-Phe-Arg-AMC
hydrolysis with HB3-leuR1 fractions after leupeptin loading indicates reduced leupeptin uptake through the mutant PSAC. AU, arbitrary units. (C) Percent
inhibition of papain-mediated Z-Phe-Arg-AMC hydrolysis, calculated from rates over first 10 min, measured as described for panel B.
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Because resistance to vinyl sulfone protease inhibitors un-
dergoes partial reversion upon removal of selective pressure
(31), we maintained continuous cultures of HB3-leuR1 without
leupeptin pressure for 3 months. Subsequent challenge re-
vealed that the progeny were still resistant to leupeptin’s toxic
effects. These parasites also exhibited quantitatively un-
changed reductions in sorbitol permeability (osmotic lysis data
not shown), indicating that the selected resistance is stable for
many generations and suggesting one or more mutations in the
genes encoding PSAC activity. In contrast to these findings,
another recently identified functional PSAC mutant undergoes
rapid reversion in the absence of selective pressure (14).
We also used in vitro growth inhibition studies to examine
whether the selection of leupeptin resistance confers resistance
to other protease inhibitors or to known antimalarial drugs.
None of these other agents exhibited a significantly altered
IC50 (Table 2). These compounds may enter infected cells
primarily via other mechanisms, such as direct partitioning
across membranes; alternatively, they may require uptake via
PSAC but have relatively preserved permeabilities in this mu-
tant. Blasticidin S was also tested because of its use to select for
a distinct PSAC mutant (14). It appears to have some cross-
resistance with leupeptin (Table 2), consistent with the pro-
posal that it requires PSAC-mediated uptake to reach its par-
asite ribosomal target. Additional studies will be necessary to
confirm this hypothesis.
Anticipating similar resistance to other compounds. Ac-
quired resistance to antimalarial compounds via reduced
PSAC-mediated uptake represents a new resistance mecha-
nism that may be discouraging to drug discovery and develop-
ment programs. Is it possible to predict which new drug can-
didates are most susceptible? To develop a suitable test, we
evaluated the effects of NPF-1 on parasite killing by leupeptin.
Because NPF-1 and other PSAC antagonists also inhibit par-
asite growth in vitro, we performed growth inhibition dose-
response assays with various mixtures of leupeptin and NPF-1
and used an isobologram to examine possible interactions (Fig.
6). If parasite growth inhibition by NPF-1 and leupeptin in-
volves noninteracting mechanisms, then the IC50 for each mix-
ture should fall on the straight line connecting the effects of the
inhibitors applied individually (Fig. 6, solid line). In contrast to
this prediction, we observed a marked shift to the right of this
line in our experiments, indicating that NPF-1 strongly antag-
onizes the toxicity of leupeptin. This antagonism is consistent
with a critical role for PSAC in leupeptin uptake: NPF-1 pre-
sumably limits leupeptin’s toxicity by blocking PSAC-mediated
access to intracellular protease targets. We also performed
growth inhibition studies with combinations of leupeptin and
two other high-affinity, high-specificity PSAC antagonists (un-
published data). Both of these agents produced similar reduc-
tions in leupeptin toxicity (data not shown), excluding antag-
onism due to mechanisms other than reduced leupeptin
uptake. Thus, in vitro antagonism of a drug candidate’s toxicity
by one or more PSAC antagonists can confirm a dependence
on PSAC-mediated uptake. This simple test can be used with
any new drug candidate to evaluate if resistance can arise
through selection of reduced uptake via an altered PSAC.
DISCUSSION
Acquired resistance to antimalarial drugs may be the single
greatest problem facing both prophylaxis and treatment of
malaria worldwide. Indeed, prior to the development of chlo-
roquine resistance, single-dose therapy was generally consid-
ered definitive treatment for P. falciparum malaria cases in all
parts of the world. Over some 20 years, gradually increasing
rates of parasite resistance to chloroquine led to the need for
increases in the administered dose, the need for the use of
multiple doses over 3 to 7 days, and outright treatment failure.
Acquired chloroquine resistance had a devastating effect on
malaria treatment and contributed significantly to abandon-
ment of the global malaria eradication program launched by
the World Health Organization (37).
Understanding the drug resistance mechanisms used by ma-
laria parasites not only is an important step in attempts to
restore the utility of existing antimalarials but also is critical to
FIG. 6. Isobologram showing that NPF-1, a specific PSAC inhibi-
tor, markedly antagonizes leupeptin’s growth-inhibitory effect. Each
symbol represents the concentrations of these two agents that together
produce 50% parasite killing. The solid diagonal represents the line of
additivity expected for noninteracting combinations. The results are
typical of those for five independent experiments. The marked right-
ward shift of this profile reflects the higher concentrations of leupeptin
required when PSAC is inhibited by NPF-1.
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E-64 3.69






 0.15 1.15 
 0.21
Chloroquine 10.41
 0.24 11.57 
 1.80
Artemisinin 8.36
 1.98 7.71 
 1.17
Quinine 77.13
 4.63 73.96 
 1.76
a Growth inhibition studies with HB3 and HB3-leuR1 were carried out as
described in Materials and Methods.
b Mean IC50s 
 SEMs were determined from three or more dose-response
experiments each and are presented in M (leupeptin, E-64, pepstatin A, and
blasticidin S) or nM (the other agents). There were no significant differences for
agents other than leupeptin between the two parasites, but this may reflect our
small sample sizes. The trend toward higher E-64 and blasticidin S IC50s in the
mutant may reflect partial cross-resistance with leupeptin.




arch 8, 2014 by W







rational drug discovery and development programs. Molecular
and biochemical studies have provided evidence for three dis-
tinct resistance mechanisms in malaria parasites to date. First,
mutations in the parasitic target may reduce the drug’s efficacy
by lowering the affinity of the drug-target interaction or by
sustaining the activity of the target in spite of drug binding.
Important examples include sulfadoxine and pyrimethamine,
which act synergistically to inhibit dihydropteroate synthase
and dihydrofolate reductase, key enzymes in folate biosynthe-
sis. Resistance to these drugs is primarily mediated by point
mutations in both enzymes that reduce inhibitor affinity (21,
34). A second acknowledged, but less well characterized,
mechanism is the upregulated expression of target enzymes
through genome-level amplification or increased transcription
(16, 31, 33); this strategy may sustain the needed parasite
activity despite the presence of an inhibitor. The third ac-
knowledged mechanism of resistance to antimalarials is
through active extrusion of an unmetabolized drug, a mecha-
nism that restores target activity by reducing the drug concen-
tration at the target site. This may be the primary mechanism
of resistance to chloroquine (13) and possibly also other anti-
malarial drugs (12).
Our study identifies a novel mechanism of antimalarial drug
resistance. We generated in vitro leupeptin resistance and per-
formed biochemical, molecular, and biophysical studies along
with growth inhibition experiments to explore possible mech-
anisms. Our biochemical studies did not detect upregulated
activity or reduced leupeptin sensitivity of digestive vacuolar
proteases. There were also no point mutations in falcipain-2 or
falcipain-3 or marked changes in the expression of blood-stage
protease genes. Instead, significant changes in the erythrocyte
membrane permeability of organic solutes were identified. Sin-
gle-channel recordings confirmed that these changes resulted
from an altered PSAC. We linked leupeptin resistance to these
changes by determining that leupeptin entry into infected
erythrocytes occurs primarily via PSAC and that resistant par-
asites exhibit markedly reduced leupeptin uptake. Thus, our
studies implicate reduced leupeptin permeability via PSAC as
the primary mechanism of resistance to leupeptin’s growth-
inhibitory effects. This proposal is consistent with leupeptin’s
net positive charge and bulky structure, which limit its trans-
port across membranes in most other cell types (19). The large
discrepancy between the required extracellular leupeptin con-
centration (IC50, 18 M for wild-type parasites; Fig. 1A) and
its activity against extracts of parasite proteases (K0.5, 87 nM;
Fig. 2) is consistent with rate-limiting uptake at the erythrocyte
membrane. In this context, mutations that result in reduced
passive leupeptin uptake should readily permit the acquisition
of resistance at the observed levels. Finally, this proposal is
also consistent with studies demonstrating the increased per-
meability of other bulky solutes after infection with plasmodia
(3, 5, 27). PSAC appears to mediate all of these changes.
In vitro resistance to blasticidin S by malaria parasites may
also be due to reduced PSAC-mediated uptake (14); definitive
evidence will require studies of blasticidin S transport across
the erythrocyte membrane and examination of possible
changes in its intracellular targets. In either case, the mutant
described here exhibits less dramatic changes in channel prop-
erties, with higher sorbitol permeation and larger single-chan-
nel Cl currents than the blasticidin S-resistant mutant de-
scribed previously. Consistent with this, we found that the
growth rate of HB3-leuR1 was indistinguishable from that of
HB3 in the absence of leupeptin (data not shown), whereas a
clear fitness cost was associated with blasticidin S resistance
(14).
A separate study recently generated a parasite that exhibited
in vitro resistance to morpholine urea-leucine-homophenylala-
nine-phenyl vinyl sulfone (31), a more specific cysteine pro-
tease inhibitor (35). In contrast to the findings of our studies
with leupeptin, vinyl sulfone resistance was mediated by the
combination of upregulated cysteine protease activity and de-
creased vinyl sulfone accumulation. The change in accumula-
tion could have resulted from either reduced passive uptake or
increased efflux across one or more membranes. In contrast to
this uncertainty, our studies indicate that changes in leupeptin
transport localize to the erythrocyte membrane instead of one
or more parasite-associated membranes, because uptake into
the erythrocyte cytosol was specifically measured (Fig. 5). This
was achieved with 0.05% saponin to selectively permeabilize
the erythrocyte membrane without compromising intracellular
parasite membranes. Because parasite-induced transport across
the erythrocyte membrane is generally accepted to be primarily
passive (32), reduced leupeptin uptake probably represents
reduced passive uptake and not increased efflux. Moreover, the
effects of NPF-1 on leupeptin uptake (Fig. 5A) strongly suggest
transport via PSAC, an ion channel that mediates only passive
transport. Finally, vinyl sulfone resistance in the previous study
was associated with only modest changes in leupeptin sensitiv-
ity, consistent with resistance via mechanisms distinct from the
one described here.
The identification of a new resistance mechanism provides
yet another challenge to groups working on the discovery and
development of antimalarials. Fortunately, our findings sug-
gest some obvious guidelines for reducing the risk of the ac-
quisition of resistance via this mechanism. Drug leads that
have high molecular weights, cigar-shaped structures, and net
charge or high polarity are most likely to require PSAC-medi-
ated uptake; indeed, both leupeptin and blasticidin S meet
these criteria and have negative calculated logP values. Anti-
malarial leads that meet these criteria and that are nontoxic to
mammalian cells lacking PSAC-like channels may be especially
susceptible to this resistance mechanism. Antagonism of a can-
didate drug’s in vitro growth-inhibitory effects by specific
PSAC antagonists, as described here, would be highly sugges-
tive and should result in increased vigilance.
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